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Objective: To validate the methodology for the Dynamic Insulin Sensitivity and Secretion 29 
Test (DISST) and to demonstrate its potential in clinical and research settings. 30 
 31 
Methods: 123 men and women had routine clinical and biochemical measurements, an oral 32 
glucose tolerance test and a DISST. For the DISST, participants were cannulated for blood 33 
sampling and bolus administration. Blood samples were drawn at t=0, 10, 15, 25 and 35 34 
minutes for measurement of glucose, insulin and C-peptide. A 10g bolus of intravenous 35 
glucose at t=5 minutes and 1U of intravenous insulin immediately after the t=15 minute 36 
sample were given. Fifty participants also had a hyperinsulinaemic euglycaemic clamp. 37 
Relationships between DISST insulin sensitivity (SI) and the clamp, and both DISST SI and 38 
secretion and other metabolic variables were measured.  39 
 40 
Results: A Bland-Altman plot showed little bias in the comparison of DISST with the clamp; 41 
with DISST underestimating the glucose clamp by 0.1·10-2·mg·l·kg-1·min-1·pmol-1 (90%CI -42 
0.2 to 0). The correlation between SI as measured by DISST and the clamp was 0.82, the c 43 
unit for the ROC analysis for the two tests was 0.96. Metabolic variables showed significant 44 
correlations with DISST IS, and the second phase of insulin release. DISST also appears able 45 
to distinguish different insulin secretion patterns in individuals with identical SI values. 46 
 47 
Conclusions: DISST is a simple, dynamic test that compares favourably with the clamp in 48 
assessing SI and allows simultaneous assessment of insulin secretion. DISST has the potential 49 
to provide even more information about the pathophysiology of diabetes than more 50 
complicated tests. 51 
 52 
Key Words: insulin sensitivity, beta cell function, insulin secretion, insulin resistance, type 2 53 
diabetes mellitus. 54 
 55 
Abbreviations: BMI: body mass index. DBP: Diastolic blood pressure. DISST: dynamic 56 
insulin sensitivity and secretion test. FPG: fasting plasma glucose. HOMA: homeostasis 57 
model assessment. IGT: impaired glucose tolerance. NGT: normo-glucose tolerance. IQR: 58 
interquartile range. IVGTT: intravenous glucose tolerance test. NGT: normal glucose 59 
tolerance. OGTT: oral glucose tolerance test. ROC: receiver operator curve. SBP: systolic 60 
blood pressure. SI: insulin sensitivity. 61 
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1. Introduction 62 
Insulin resistance and β-cell dysfunction are prerequisites for the development of impaired 63 
fasting glucose, impaired glucose tolerance (IGT) and type 2 diabetes mellitus.  However, the 64 
lack of a relatively simple test to reliably quantify both insulin sensitivity and secretion make 65 
it difficult to examine heterogeneity in epidemiological studies of prediabetes and diabetes 66 
and explore pathophysiology in studies of prevention and treatment. We have described a 67 
simple test – DISST [1, 2] which can provide quantitative measures of insulin sensitivity and 68 
insulin secretion.  69 
 70 
The present paper has utilised a simple version of the DISST which involves five blood 71 
samples taken over a 35-minute protocol that uses low-dose, intravenous glucose (10g) and 72 
insulin (1U) boluses as stimulus.  Thus, it is relatively short, and considerably less labour 73 
intensive than the gold-standard glucose clamp.  The DISST model and identification method 74 
enable the sparse sampling protocol by fitting and refining physiological responses to the 75 
measured data [3, 4]. Unlike previous models, the DISST model of glucose and insulin 76 
kinetics accounts for patient-specific losses of insulin to the liver and the kidneys, saturation 77 
of insulin clearance at high concentrations and diffusion and mass conservation of insulin 78 
between the plasma and the interstitium [4]. In addition to assessing insulin sensitivity the test 79 
can be used to assess ß-cell function using established methods [5]. This aspect of the DISST 80 
is not novel. 81 
 82 
The availability of such a test which can physiologically assess insulin sensitivity and 83 
simultaneously estimate insulin secretion provides the potential to explore heterogeneity in 84 
those who are currently labelled with the diagnosis of metabolic syndrome, prediabetes or 85 
type 2 diabetes mellitus, and to further understand responses to treatment with lifestyle 86 
measures and pharmacology. 87 
 88 
This paper provides a validation of the DISST in the assessment of insulin sensitivity and 89 
illustrates its potential use.  90 
 91 
 92 
2. Methods 93 
Data from two separate studies undertaken by the same group of investigators have been 94 
combined.  The first study cohort included 10 lean (BMI<25), 20 overweight (BMI>25, <30) 95 
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and 20 obese (BMI>30) participants, with even gender distribution in each category.  The 96 
second study cohort included 73 women who were considered at-risk of metabolic diseases 97 
either by a BMI>25 or BMI>23 and a family history of diabetes.  Participants were excluded 98 
if they suffered from any major medical or psychiatric illness or were known to have diabetes.  99 
Ethical approval for the first study was from the Upper South A Regional Ethics Committee. 100 
The second study was approved by the University of Otago Ethics Committee. 101 
 102 
All 123 participants had weight, waist circumference (the midpoint of the lowest rib and 103 
highest part of the hip) and resting blood pressure measured.  The 50 participants in the first 104 
study underwent a glucose clamp, the 4-sample OGTT and DISST protocols within 8 days, 105 
with at least one day between tests.  The tests were given in random order such that each of 106 
the six possible combinations were equally represented.  A pre-randomised test order was 107 
allocated to each participant based on order of recruitment.  Participants of the second study 108 
underwent the DISST and the 2-sample OGTT in order to classify them as having a normal, 109 
or impaired glucose tolerance or type 2 diabetes [6]. All participants fasted from 10pm the 110 
night before each test and the tests were begun at 9am. 111 
 112 
OGTT protocol 113 
Fifty participants from the first study had an OGTT for assessment of insulin sensitivity using 114 
the Matsuda method [7]. Participants were given a standard 75g oral glucose load after a 115 
fasting blood sample. Further blood samples were collected at 30, 60 and 120 minutes. 116 
HOMA was also calculated for the first study participants using the basal assays of the OGTT 117 
and previously published methods [8, 9]. 118 
 119 
DISST protocol 120 
Participants had a cannula inserted into the antecubital fossa for blood sampling and bolus 121 
administration.  Blood samples were drawn at t=0, 10, 15, 25 and 35 minutes and glucose, 122 
insulin and C-peptide was measured on these samples.  A 10g bolus of intravenous glucose 123 
was given at t=5 minutes and 1U of Actrapid insulin was given immediately after the t=15 124 
minute sample.  Participants were required to remain at the clinic for 30 minutes after the test 125 
and were provided with a small meal or snack. 126 
 127 
The parameter identification methods of dynamic tests (such as the DISST) are sensitive to 128 
the timing of samples. Thus, the actual sample times were recorded.  The integral method is 129 
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used to identify model-based insulin sensitivity (SI), glucose distribution volume (Vg), first-130 
pass (xL) and subsequent hepatic insulin clearance (nL) [3, 10].  Metrics of β cell function are 131 
derived from insulin production profiles that are deconvolved from interpolated C-peptide 132 
data following the established method of Van Cauter et al. [3, 5]. The DISST model and 133 
identification method are briefly repeated in Appendix 1. 134 
 135 
Three metrics were used to quantify β cell function.  The basal rate (Ub) indicates the rate of 136 
insulin production the participant requires to maintain a constant fasting glucose 137 
measurement.  AUC10 measures the first phase insulin production and is defined as the 138 
amount of insulin produced above the basal rate during the ten minutes after the glucose 139 
bolus.  AUC2nd quantifies the participant’s second phase of insulin production as the total 140 
amount of insulin produced during the 20 minutes after the period measured by AUC10. 141 
 142 
The DISST method used in this study is a simpler version of the original DISST [3, 4] using 5 143 
blood samples instead of 9. The impact of such sparse sampling on insulin sensitivity and 144 
insulin secretion metrics have been shown to be limited in previous studies [4, 11, 12]. 145 
Previous analysis by Docherty et al. found that insulin sensitivity and production values were 146 
barely affected by the omission of samples from the frequently sampled protocol used in the 147 
DISST pilot study [12]. The five-sample method was not significantly different from the 148 
original 9-sample method. The correlations between the outcomes of the pilot sampling 149 
protocol and the sampling protocol used here were r=0.90, 1.0, 1.0, and 0.89 for SI, Ub, 150 
AUC10, and AUC2nd, respectively. 151 
 152 
Glucose Clamp protocol 153 
The 50 participants in the first study underwent a glucose clamp. Participants had two 154 
cannulae inserted: one in the antecubital fossa; the other, a retrograde cannula, inserted in the 155 
dorsum of the hand.  The hand was heated so that arterialised blood was obtained for 156 
sampling.  Insulin was infused at 280pmol/min/m2 and glucose was infused to achieve a target 157 
glucose concentration of 81mg/dl, or at the fasting level if this was between 72 and 90 mg/dl.  158 
The test lasted for 2 to 2.5 hours and data from the last 40 minutes was used to calculate 159 
insulin sensitivity index (ISI) in mg·l·kg-1·min-1·pmol-1 [13]. Participants were required to 160 





Unit correction 164 
As the standard DISST and the clamp SI values have different units, a conversion needs to be 165 
made to compare the magnitude of values across the two different tests.  The model-based SI 166 
identified by the DISST measures the glucose disposal as a function of the available glucose, 167 
glucose distribution volume and the modelled interstitial insulin. However, the clamp 168 
measures as a function of the absolute glucose disposal, steady-state plasma insulin 169 
concentration and the participant’s bodyweight. Thus to achieve common units the DISST SI 170 
values must be converted:  171 
 172 
where: Gb is the basal glucose concentration [mmol·l-1], Vg is the identified distribution 173 
volume of glucose [l], BW is bodyweight [kg],  is the steady state ratio between plasma and 174 
interstitial insulin (0.5) [14], and the ‘1000’ coefficient converts from dl to l and multiplies by 175 
100 in accordance with the standard practice for reporting clamp metrics.  176 
 177 
Laboratory analysis 178 
Glucose values for the first study were analysed using YSI 2300 stat plus Glucose and L-179 
Lactate analyser using whole blood.  These were converted to plasma glucose with the 180 
equation recommended by the analyser manufacturer:  181 
 182 
Plasma glucose levels taken in the second study were measured enzymatically with Roche 183 
kits and calibrators on a Cobas Mira Analyser. Samples for insulin and C-peptide were 184 
separated immediately and frozen.  Measurements of insulin were undertaken by the Endolab, 185 
Canterbury Health Laboratories for the first study and by the University of Otago Nutrition 186 
Laboratory for the second study. Both laboratories used Roche Elecsys® after Peg 187 
precipitation of immunoglobulins (Roche Diagnostics, Mannheim, Germany). Consistency 188 
between laboratories was maintained. All C-peptide measurements were undertaken by 189 
Endolab, Canterbury Health Laboratories using the Roche Elecsys® method.  Serum 190 
cholesterol and triglycerides were measured enzymatically with Roche kits and HDL was 191 
measured in the supernatant after precipitation of apolipoprotein B containing lipoproteins 192 
with phosphotungstate/magnesium chloride solution [15].  193 
 194 
Statistical methods 195 
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The data are presented as means and standard deviations or median and upper and lower 196 
quartiles. Correlations were used to describe the associations between the insulin sensitivity 197 
values. A Bland Altman plot was used to compare the DISST with the glucose clamp. 198 
Analysis of variance was used to compare the three groups derived from the first insulin 199 
phase (AUC10) and those derived from the second insulin phase (AUC2nd).  Comparisons 200 
between those with IGT and those with NGT are also presented.   201 
 202 
3. Results 203 
The range of DISST insulin sensitivity values for the 123 individuals was 0.2 to 3.4·10-4 204 
·l·pmol-1·min-1 with a mean of 1.1 (SD 0.64), median 1.0 (IQR 0.7 to 1.4). The range for 205 
insulin sensitivity estimated by the glucose clamp (n=50) was 0.1 to 2.3·10-2·mg·l·kg-1·min-206 
1·pmol-1, mean 1.0 (SD 0.61), median 0.9 (IQR 0.6 to 1.4).   207 
 208 
The Bland-Altman plot (Figure 1) shows the bias between the two tests, where the DISST 209 
underestimated the glucose clamp by 0.1·10-2·mg·l·kg-1·min-1·pmol-1 (95% CI -0.2 to 0.0).  210 
The limits of agreement were -0.9 to 0.7·10-2·mg·l·kg-1·min-1·pmol-1. Figure 2 shows the 211 
correlation between the DISST and the glucose clamp (r=0.82). Figure 3 presents a ROC 212 
curve for the DISST compared to the glucose clamp (c unit=0.96 using an insulin resistance 213 
cut off for the glucose clamp of 1.0·10-2·mg·l·kg-1·min-1·pmol-1 [9]).  214 
 215 
Correlations between the DISST and the variables known to be associated with insulin 216 
resistance are shown in Table 1 as well as the correlations between the DISST and the HOMA 217 
and the Matsuda index.   218 
 219 
Characteristics of those separated into tertiles of first phase and second phase insulin secretion 220 
are shown in Tables 2 and 3. Of note, those with IGT were spread evenly across the tertiles of 221 
first phase insulin secretion. However, second phase insulin secretion was significantly 222 
associated with all of the features of the metabolic syndrome. Table 4 compares insulin 223 
secretion metrics across the NGT and IGT subgroups. In accordance with previous 224 
observations [16-18], the second phase insulin secretion was significantly higher in those with 225 
IGT.   226 
 227 
Figure 4 shows the results of the DISST test for insulin sensitivity and insulin secretion 228 
metrics for four insulin resistant participants. All of the examples in this figure had the same 229 
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insulin sensitivity measured by the clamp (0.8·10-2·mg·l·kg-1·min-1·pmol-1), however the 230 
DISST profiles showed clear differences between these individuals. The range of insulin 231 
sensitivity estimated by the DISST was 0.95 to 1.36·10-4·l·pmol-1·min-1for these participants.  232 
However, of particular note were the distinct insulin production characteristics of these 233 
participants. Participants A and B showed contrasting profiles to participants C and D in 234 
terms of the magnitude of first phase release of insulin. Participant C had an increased second 235 
phase, and blunted first phase of insulin production, which coupled with an inability to return 236 
to the basal glucose concentration within 30 minutes, indicated insulin resistance and β cell 237 
dysfunction for this participant. 238 
 239 
No serious adverse events were observed in participants and there were no episodes of 240 
symptomatic hypoglycaemia following the DISST.   241 
 242 
4. Discussion 243 
The DISST estimates both insulin sensitivity and β cell function including the first and second 244 
phases of insulin release. The protocol is well accepted by participants, and is straightforward 245 
to perform. The low-dose and low-intensity DISST protocol is unique in that it results in 246 
insulin concentrations that are comparable with daily excursions and are not affected by dose-247 
dependent saturation effects [19] whereas established tests rely on non-physiological doses 248 
that exceed saturation level for insulin action [20, 21]. Thus, the model-based DISST can 249 
more directly account for dosing differences than the simpler M/I model of glucose clearance 250 
and uptake used in the clamp assessment, which varies directly with the insulin dosing due to 251 
insulin effect saturation [20, 21]. As a result, DISST SI values are more directly comparable 252 
across studies [3].   253 
 254 
The DISST concurrently allows an assessment of insulin secretion with insulin sensitivity. 255 
The insulin secretion identification method was validated by Van Cauter et al. [5] and has 256 
been used by many leading insulin sensitivity research groups [22-25]. The second phase 257 
values of insulin secretion obtained from the low-intensity DISST correlated well with 258 
metabolic risk factors, and distinguished IGT and NGT subgroups. The DISST offers the 259 
possibility of relating the insulin secretion rate to their insulin sensitivity status, which is 260 
potentially useful in research and clinical practice. Insulin secretion typically increases with 261 
insulin resistance in the early stages of IGT and type 2 diabetes, but declines as β cell function 262 
is lost [13, 26, 27]. Thus, as illustrated in Figure 4, apparently healthy NGT individuals can 263 
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have insulin production rates similar to those of individuals that have considerable loss of β 264 
cell function. Current tests do not distinguish between these individuals with different insulin 265 
secretion responses [16].  266 
 267 
The DISST insulin sensitivity values were converted to mimic the units of the gold-standard 268 
clamp, and thus could be compared to clamp values in terms of both correlation and bias.   269 
Furthermore, Table 1 compared the DISST insulin sensitivity values to co-factors related to 270 
insulin resistance and produced expected outcomes [28].  The moderate correlations presented 271 
in Table 1 must be considered with respect to the low resolution of the co-factors presented in 272 
terms of characterising insulin resistance.  273 
 274 
In contrast to insulin sensitivity, there is no established gold standard for the evaluation of 275 
insulin secretion.  Thus, this investigation has evaluated the insulin secretion values estimated 276 
by the DISST by comparison with established metabolic markers of insulin resistance.  277 
Furthermore, the low-intensity 5 sample protocol has been validated by Lotz et al. [11].   278 
 279 
The DISST requires a significantly less intensive protocol than insulin sensitivity tests that 280 
produce similar correlations to the clamp [29-31].  The DISST can achieve this level of 281 
accuracy with improved parameter identification methods [10] and the adoption of a single 282 
model variable for glucose decay. The identification of two metrics that model glucose 283 
clearance has been an issue in previous studies using the Minimal Model approach [32, 33] 284 
and strategies used to ameliorate this problem require either Bayesian techniques [34, 35] or 285 
arduous, clinically intense, frequently sampled protocols.  However, it has been shown that 286 
fixing the glucose dependent clearance term (that has limited clinical value) maximises 287 
identification stability and allows the considerably less intense protocol of the DISST to 288 
produce a stable and relevant metric of insulin sensitivity [4, 12].  The overall reduction in 289 
clinical intensity and improved parameter stability offered by the DISST comes at the cost of 290 
increased parameter identification complexity.  However, this is a positive development, as it 291 
allows a lower per participant cost than the established, simple-model, intense-protocol tests 292 
for insulin sensitivity. 293 
 294 
More intensive tests such as the glucose clamp [36] and the IVGTT [37] require specialist 295 
training for those performing the tests, involve a greater participant burden and are more 296 
costly, all of which generally limit their use to small research studies. They appear to be 297 
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comparable tests, although the IVGTT, with a coefficient of variation of 14 to 30%, is less 298 
reliable than the glucose clamp, coefficient of variation of 6 to 10%. The particularly high 299 
repeatability has earned the glucose clamp gold standard status [16]. However, the glucose 300 
clamp yields different results at different infusion rates which complicates comparisons 301 
between studies [20, 21]. The basic glucose clamp assumes all endogenous glucose and 302 
insulin secretion is fully suppressed, that all glucose uptake is mediated by insulin and that the 303 
uptake rate is proportional to the plasma insulin concentration [36]. In fact, insulin 304 
independent glucose uptake occurs and can be constant (to the brain and the central nervous 305 
system) or dependent on glucose concentration [38]. This is accounted for by the DISST [3].  306 
 307 
An earlier study involving repeated tests demonstrated that the DISST was as reliable as the 308 
glucose clamp in measuring insulin sensitivity [2]. We report here a strong correlation 309 
between insulin sensitivity measured by the DISST and the glucose clamp (R=0.82). It is 310 
noteworthy that on average the DISST only under-estimated the clamp ISI by 0.1·10-311 
2·mg·l·kg-1·min-1·pmol-1, even though there were substantial differences between the two 312 
protocols. The ROC analysis, which is usually used to compare two very different tests, 313 
indicates that the DISST and the glucose clamp are reasonably comparable. Although both 314 
tests relate the rate of glucose uptake to an insulin concentration, the clamp involves a steady 315 
state, hyper-physiological protocol with suppression of insulin and glucose production and 2-316 
3 hours of frequent sampling, whereas the DISST protocol involves only 35-minutes of less 317 
frequent sampling and does not significantly suppress endogenous insulin or glucose 318 
production. In contrast to the clamp, the DISST insulin sensitivity is a function of interstitial 319 
insulin and is measured with glucose and insulin concentrations that are typical of daily life.  320 
Furthermore, the DISST accounts for non-insulin mediated glucose uptake, which the clamp 321 
assumes is negligible.  Thus, while the clamp was designed to maximise repeatability, the 322 
DISST was designed to be relevant to the participant’s metabolic physiology.  323 
 324 
In conclusion, we believe the DISST is a relatively low cost, practical test which yields 325 
substantially more information regarding glucose and insulin responses to stimuli than other 326 
available tests. DISST is safe and reliable and allows a reasonable estimation of insulin 327 
sensitivity. In addition estimates of insulin secretion can be obtained at the same time. It is a 328 
test which could be applied in clinical or research settings; either where a glucose clamp 329 
might be used or in larger trials where either an OGTT or the HOMA would be used. If the 330 
DISST were to be applied widely, it could greatly enhance our understanding of the 331 
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pathophysiology of type 2 diabetes mellitus and help to more clearly differentiate the very 332 
heterogeneous group who are at risk of type 2 diabetes mellitus. 333 
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Appendix 1 363 
The DISST defines the pharmaco-kinetics/dynamics of C-peptide, insulin and glucose with a 364 
physiological model.  The model relates the rate of glucose decay to the concentration of 365 
insulin available in the interstitium to provide a metric of insulin sensitivity.  The model 366 


















where: k1-3 are kinetic parameters (1/min); C and Y are plasma and interstitial C-peptide 369 
concentrations, respectively (pmol/l); uen(t) is the time variant rate of insulin production 370 
(pmol/min); I and Q are the plasma and interstitial insulin concentrations respectively 371 
(pmol/l); Vp and Vq are the distribution volumes of insulin in the plasma and interstitium 372 
respectively (l); nK is the rate of insulin clearance by the kidney (1/min); nI is the transition 373 
rate of insulin between the plasma and interstitium (l/min); nL is the rate of hepatic insulin 374 
clearance (min-1); αI is the saturation of hepatic insulin clearance (l/pmol); nC is the rate of 375 
insulin clearance to cells (1/min); uex(t) is the bolus input of insulin (pmol); xL is the hepatic 376 
first pass extraction of insulin (1); pgu is the glucose dependent (insulin-independent) rate of 377 
glucose disposal (1/min); SI is the modelled insulin sensitivity (l/pmol/min); P is the glucose 378 
bolus (mmol); Vg is the volume of distribution of glucose (l); G is the glucose concentration 379 
(mg/dL) and the ‘b’ subscript denotes the basal concentration of the respective species.  380 
 381 
The measured C-peptide, insulin and glucose data is used to identify participant-specific 382 
parameters with methods that have been exhaustively defined and justified in previous 383 
14 
 
publications [2-4, 10].  However, the methods will be summarised in brief:  Initially, a false 384 
basal data point with concentrations equal to the measured basal sample was added 385 
immediately prior to the glucose bolus.  This ensured that the influence of the basal period on 386 
the identified variables was equal across participants.  The kinetic parameters of Equations 1 387 
and 2 are quantified using functions of participant weight, height sex and age that were 388 
defined by Van Cauter et al. [5]. A piece-wise linear interpolation of the C-peptide data was 389 
used with these values in a deconvolution of Equations 1 and 2 to produce an endogenous 390 
insulin production profile (uen(t)).  Finally, SI, Vg, nL and xL were identified using the 391 
deconvoluted endogenous insulin production profile, insulin and glucose data, Equations 3-5 392 
and the integral method [3, 10].  Note that the t=10 minute glucose sample is assumed to be 393 
affected by mixing and is thus ignored in the identification of SI and Vg and is omitted from 394 





1 Lotz TF, Chase JG, McAuley KA, et al. Transient and steady-state euglycemic clamp 398 
validation of a model for glycemic control and insulin sensitivity testing. Diabetes 399 
Technol Ther 2006;8(3):338-46 400 
2 Lotz TF, Chase JG, McAuley KA, et al. Monte Carlo analysis of a new model-based 401 
method for insulin sensitivity testing. Comput Methods Programs Biomed 402 
2008;89(3):215-25 403 
3 Lotz TF, Chase JG, McAuley KA, et al. Design and clinical pilot testing of the model-404 
based dynamic insulin sensitivity and secretion test (DISST). J Diabetes Sci Technol 405 
2010;4(6):1408-23 406 
4 Lotz T. High resolution clinical model-based assessment of insulin sensitivity. (2007) 407 
PhD Thesis Department of Mechanical Engineering, University of Canterbury, 408 
Christchurch, New Zealand,  http://hdl.handle.net/10092/1571  409 
5 Van Cauter E, Mestrez F, Sturis J, et al. Estimation of insulin secretion rates from C-410 
peptide levels. Comparison of individual and standard kinetic parameters for C-411 
peptide clearance. Diabetes 1992;41(3):368-77 412 
6 ADA. Diagnosis and Classification of Diabetes Mellitus. Diabetes Care 413 
2006;29(suppl_1):S43-S48 414 
7 Matsuda M and DeFronzo RA. Insulin sensitivity indices obtained from oral glucose 415 
tolerance testing: comparison with the euglycemic insulin clamp. Diabetes Care 416 
1999;22(9):1462-1470 417 
8 Matthews DR, Hosker JP, Rudenski AS, et al. Homeostasis model assessment: insulin 418 
resistance and beta-cell function from fasting plasma glucose and insulin 419 
concentrations in man. Diabetologia 1985;28(7):412-9 420 
9 McAuley KA, Williams SM, Mann JI, et al. Diagnosing insulin resistance in the 421 
general population. Diabetes Care 2001;24(3):460-4 422 
16 
 
10 Hann CE, Chase JG, Lin J, et al. Integral-based parameter identification for long-term 423 
dynamic verification of a glucose-insulin system model. Comput Methods Programs 424 
Biomed 2005;77(3):259-70 425 
11 Lotz TF, Goltenbolt U, Chase JG, et al. A minimal C-peptide sampling method to 426 
capture peak and total prehepatic insulin secretion in model-based experimental 427 
insulin sensitivity studies. Journal of Diabetes Science and Technology 2009;3(4):875-428 
86 429 
12 Docherty PD, Chase JG, Lotz TF, et al. Evaluation of the performances and costs of a 430 
spectrum of DIST protocols. Eds E. Carson UK International Conf on Control 431 
Coventry, UK 2010 6-pages 432 
13 Ferrannini E and Mari A. How to measure insulin sensitivity. J Hypertens 433 
1998;16(7):895-906 434 
14 Barrett EJ, Eggleston EM, Inyard AC, et al. The vascular actions of insulin control its 435 
delivery to muscle and regulate the rate-limiting step in skeletal muscle insulin action. 436 
Diabetologia 2009;52(5):752-64 437 
15 Assmann G, Schriewer H, Schmitz G, et al. Qunatification of high-density-lipoprotein 438 
cholesterol by precipitation with phosphotungstic acid/MgCl2. Clin Chem 439 
1983;29(12):2026-30 440 
16 Pacini G and Mari A. Methods for clinical assessment of insulin sensitivity and beta-441 
cell function. Best Pract Res Clin Endocrinol Metab 2003;17(3):305-22 442 
17 Ferrannini E. Insulin resistance is central to the burden of diabetes. Diabetes Metab 443 
Rev 1997;13(2):81-6 444 
18 Cobelli C, Toffolo G, Dalla Man C, et al. Assessment of beta-cell function in humans, 445 
simultaneously with insulin sensitivity and hepatic extraction, from intravenous and 446 
oral glucose tests. Am J Physiol Endocrinol Metab 2007;293(1):E1-E15 447 
19 Docherty PD, Chase JG, Hann CE, et al. The identification of insulin saturation effects 448 
during the dynamic insulin sensitivity test. Open Med. Inform. J. 2010;4:141-148 449 
17 
 
20 Natali A, Gastaldelli A, Camastra S, et al. Dose-response characteristics of insulin 450 
action on glucose metabolism: a non-steady-state approach. Am J Physiol Endocrinol 451 
Metab 2000;278(5):E794-801 452 
21 Laakso M, Edelman SV, Brechel G, et al. Decreased effect of inuslin to stimulate 453 
skeletal muscle blood flow in Obese man: A novel mechanism for insulin resistance. J. 454 
Clin. Invest. 1990;85(6):1844-52 455 
22 Ferrannini E and Mari A. Beta cell function and its relation to insulin action in 456 
humans: a critical appraisal. Diabetologia 2004;47(5):943-56 457 
23 Bock G, Dalla Man C, Campioni M, et al. Pathogenesis of pre-diabetes: mechanisms 458 
of fasting and postprandial hyperglycemia in people with impaired fasting glucose 459 
and/or impaired glucose tolerance. Diabetes 2006;55(12):3536-49 460 
24 Jones CN, Pei D, Staris P, et al. Alterations in the glucose-stimulated insulin secretory 461 
dose-response curve and in insulin clearance in nondiabetic insulin-resistant 462 
individuals. J Clin Endocrinol Metab 1997;82(6):1834-8 463 
25 Mari A. Assessment of insulin sensitivity and secretion with the labelled intravenous 464 
glucose tolerance test: improved modelling analysis. Diabetologia 1998;41(9):1029-39 465 
26 Nyenwe EA, Jerkins TW, Umpierrez GE, et al. Management of type 2 diabetes: 466 
evolving strategies for the treatment of patients with type 2 diabetes. Metabolism 467 
2011;60(1):1-23 468 
27 Lin J-D, Hsia T-L, Wu C-Z, et al. The first and second phase of insulin secretion in 469 
naive Chinese type 2 diabetes mellitus. Metabolism 2010;59(6):780-786 470 
28 Urdea M, Kolberg J, Wilber J, et al. Validation of a Multimarker Model for Assessing 471 
Risk of Type 2 Diabetes from a Five-Year Prospective Study of 6784 Dansih People 472 
(Inter99). J diabetes Sci Technol. 2009;3(4):748-55 473 
29 Donner CC, Fraze E, Chen YD, et al. Presentation of a new method for specific 474 
measurement of in vivo insulin-stimulated glucose disposal in humans: comparison of 475 
this approach with the insulin clamp and minimal model techniques. J Clin Endocrinol 476 
Metab 1985;60(4):723-6 477 
18 
 
30 Steil GM, Rebrin K, Hariri F, et al. Interstitial fluid glucose dynamics during insulin-478 
induced hypoglycaemia. Diabetologia 2005;48(9):1833-40 479 
31 Galvin P, Ward GM, Walters JM, et al. A simple method for quantitation of insulin 480 
sensitivity and insulin release form an intravenous glucose tolerance test. Diabet Med 481 
1992;9(10):921-8 482 
32 Pillonetto G, Sparacino G, Magni P, et al. Minimal model S(I)=0 problem in NIDDM 483 
subjects: nonzero Bayesian estimates with credible confidence intervals. Am J Physiol 484 
Endocrinol Metab 2002;282(3):E564-573 485 
33 Caumo A, Vicini P, Zachwieja JJ, et al. Undermodeling affects minimal model 486 
indexes: insights from a two-compartment model. Am J Physiol 1999;276(6 Pt 487 
1):E1171-1193 488 
34 Callegari T, Caumo A and Cobelli C. Bayesian two-compartment and classic single-489 
compartment minimal models: comparison on insulin modified IVGTT and effect of 490 
experiment reduction. IEEE Trans Biomed Eng 2003;50(12):1301-9 491 
35 Erichsen L, Agbaje OF, Luzio SD, et al. Population and individual minimal modeling 492 
of the frequently sampled insulin-modified intravenous glucose tolerance test. 493 
Metabolism 2004;53(10):1349-54 494 
36 DeFronzo RA, Tobin JD and Andres R. Glucose clamp technique: a method for 495 
quantifying insulin secretion and resistance. Am J Physiol 1979;237(3):E214-23 496 
37 Bergman RN, Ider YZ, Bowden CR, et al. Quantitative estimation of insulin 497 
sensitivity. Am J Physiol 1979;236(6):E667-77 498 




Table 1. Correlation between the DISST insulin sensitivity and variables known to be 501 
associated with insulin resistance as well as two simple surrogates for assessing insulin 502 






SD Correlation with 
the DISST SI 
P value 
Age (years) 42 12.2 -0.16 0.09 
Waist circumference (cm) 95.5 14.9 -0.51 <0.001 
BMI (kg/m2)  31.7 6.90 -0.45 <0.001 
FPG (mg/dl) 86.4 8.64 -0.34 0.002 
Fasting triglycerides (mmol/l) 1.30 0.94 -0.27 0.002 
Fasting HDL cholesterol (mmol/l) 1.19 0.30 0.40 <0.001 
Fasting insulin (pmol/l) 78.9 75.4 -0.63 <0.001 
HOMA  2.4 2.27 -0.40 <0.001 
Matsuda OGTTa  16.9 11.0 0.56 <0.001 




Table 2. Clinical and biochemical measures by tertiles of first phase of insulin release 507 
















Age (years) 44 (12) 42 (12) 38 (13) 0.09 
Gender % Female 82 74 83 0.51 
Weight (kg) 84.5 (18.3) 86.2 (18.0) 93.4 (24.6) 0.12 
Waist (cm) 93.0 (15.0) 93.6 (12.7) 100.1 (16.1) 0.06 
BMI (kg/m2) 30.4 (6.6) 30.9 (6.0) 33.7 (7.7) 0.06 
SBP (mmHg) 120 (14) 120 (14) 123 (19) 0.69 
DBP (mmHg) 76 (10) 77 (11) 77 (8) 0.89 
Fasting triglycerides (mmol/l) 1.30 (1.40) 1.21 (0.57) 1.39 (0.64) 0.68 
Fasting HDL cholesterol (mmol/l) 1.24 (0.29) 1.22 (0.30) 1.11 (0.29) 0.09 
FPG (mg/dl) 86.4 (9.0) 82.8 (7.2) 82.8 (7.2) 0.01 
Fasting insulin (pmol/L) 61.6 (38.7) 66.9 (40.9) 109.1 (114.5) 0.007 
IGT % 7 12 15 0.54 
Insulin sensitivity (DISST)a 1.2 (0.69) 1.3 (0.69) 0.9 (0.48) 0.06 




Table 3. Clinical and biochemical measures by tertiles of second phase of insulin release 512 
(AUC2nd, from 15 to 35 minutes) during the DISST (n=123).  513 
 0-5000 
pmol of insulin 
(n=44) 
5001-8000 
pmol of insulin 
(n=38) 
8001-16000 
pmol of insulin 
(n=41) 
P value 
Age (years) 40 (12.8) 40 (11.4) 45 (12.0) 0.12 
Gender % Female 80 79 80 0.98 
Weight (kg) 76.6 (12.1) 86.0 (14.0) 102.2 (24.8) <0.001 
Waist (cm) 84.9 (8.5) 94.8 (11.5) 107.4 (14.3) <0.001 
BMI (kg/m2) 27.2 (4.2) 31.3 (4.7) 36.8 (7.5) <0.001 
SBP (mmHg) 118 (14) 119 (14) 126 (18) 0.04 
DBP (mmHg) 74 (9) 76 (8) 79 (12) 0.05 
Fasting triglycerides 
(mmol/l) 
0.86 (0.29) 1.57 (1.40) 1.51 (1.51) 0.005 
Fasting HDL cholesterol 
(mmol/l) 
1.29 (0.26) 1.29 (0.32) 0.99 (0.19) <0.001 
FPG (mg/dl) 79.2 (7.2) 82.8 (7.2) 88.2 (7.2) <0.001 
Insulin (pmol/l) 40.0 (19.2) 67.1 (24.3) 131.5 (108.5) <0.001 
IGT % 7 13 15 0.48 
Insulin sensitivity (DISST)a 1.6 (0.69) 1.1 (0.39) 0.7 (0.25) <0.001 




Table 4. Measures indicating β cell function by glucose tolerance status (n=123).  516 















All data 123 235 (103) 6,060 (3,564) 6,889 (3,320) 
NGT 109 230 (105) 5,973 (3,578) 6,660 (3,245) 
IGT 14 276 (74) 6,739 (3,502) 8,668 (3,487) 
P value  0.11 0.45 0.03 
aUb is the basal rate of insulin production; bAUC10 is the amount of insulin produced 10 517 
minutes after the glucose bolus above the basal rate; cAUC2nd is the total amount of insulin 518 






































Figure Legends 534 
 535 
Figure 1. The Bland Altman plot of insulin sensitivity estimates derived from the DISST and 536 
the glucose clamp, showing the bias between the two tests, with the DISST overestimating the 537 
glucose clamp insulin sensitivity estimate by 0.1·10-2·mg·l·kg-1·min-1·pmol-1 (95% CI -0.2 to 538 
0.0). The limits of agreement are -0.9 to 0.7·10-2·mg·l·kg-1·min-1·pmol-1. 539 
 540 
Figure 2. The correlation of the DISST and the glucose clamp insulin sensitivity values (units 541 
are 10-2·mg·l·kg-1·min-1·pmol-1). 542 
 543 
Figure 3. ROC curve of the DISST against the gold standard, the glucose clamp, c index 544 
=0.96. 545 
 546 
Figure 4. Blood glucose, plasma insulin and insulin production responses of four individuals 547 
to the DISST stimulus.  The second peak of the insulin concentration is due to the exogenous 548 
bolus of insulin used in the DISST protocol. 549 
 550 
 551 
